CoChat
Sign Up
Cited by 96Dementia and Cognitive Impairment ResearchEpigenetics and DNA MethylationAlzheimer's disease research and treatments

Blood DNA methylation as a potential biomarker of dementia: A systematic review

Open access
Fransquet, Peter D., Lacaze, Paul, Saffery, Richard, McNeil, John, Woods, Robyn, Ryan, Joanne·2018·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2017.10.002PMC PMC6810631
Open this paper in CoChat — free accountOpen PDF

Abstract

Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population‐wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty‐eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case‐control design. We emphasize the need for future longitudinal studies on large well‐characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2017.10.002

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. [3]McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939. 6610841
  2. [5]Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P. Cummings J, Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734– 46. 17616482
  3. [6]McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alz-heimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263– 9. 21514250 PMC3312024
  4. [7]The Lancet. Alzheimer’s disease: expedition into the unknown. Lancet 2016; 388: 2713. 27924761
  5. [8]Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 2016; 15: 673– 84. 27068280
  6. [9]Ahmed RM, Paterson RW, Warren JD, Zetterberg H, Brien JT, Fox NC, Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry 2014; 85: 1426. 25261571 PMC4335455
  7. [11]Takacs A, Koncz R, Mohan A, Sachdev P. Forgetfulness, stress or mild dementia? Cognitive assessment of older patients. Med Today 2017; 18: 14– 22.
  8. [12]Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447: 433– 40. 17522677
  9. [13]Harlid S, Xu Z, Panduri V, Sandler DP, Taylor JA. CpG sites associated with cigarette smoking: analysis of epigenome-wide data from the Sister Study. Environ Health Perspect 2014; 122: 673– 8. 24704585 PMC4080519
  10. [15]Zhang Y, Wilson R, Heiss J, Breitling LP, Saum KU, Schottker B, DNA methylation signatures in peripheral blood strongly predict all-cause mortality. Nat Commun 2017; 8: 14617. 28303888 PMC5357865
  11. [16]Yang R, Stocker S, Schott S, Heil J, Marme F, Cuk K, The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies. Carcinogenesis 2017; 38: 312– 20. 28426874
  12. [17]Januar V, Saffery R, Ryan J. Epigenetics and depressive disorders: a review of current progress and future directions. Int J Epidemiol 2015; 44: 1364– 87. 25716985
  13. [18]Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L. An international registry of systematic-review protocols. Lancet 2011; 377: 108– 9. 20630580
  14. [20][] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264– 9, w64. 19622511
  15. [21]Coppede F, Tannorella P, Stoccoro A, Chico L, Siciliano G, Bonuccelli U, Methylation analysis of DNA repair genes in Alzheimer’s disease. Mech Ageing Dev 2017; 161: 105– 11. 27080585
  16. [22]D’Addario C, Candia SB, Arosio B, Di Bartolomeo M, Abbate C, Case A, Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for Alzheimer’s disease, a case report. J Neurol Sci 2017; 372: 211– 6. 28017215
  17. [23]Ji H, Wang Y, Liu G, Chang L, Chen Z, Zhou D, Elevated OPRD1 promoter methylation in Alzheimer’s disease patients. PLoS One 2017; 12: e0172335. PMC5333823 28253273
  18. [24]Yamazaki K, Yoshino Y, Mori T, Yoshida T, Ozaki Y, Sao T, Gene expression and methylation analysis of ABCA7 in patients with Alzheimer’s disease. J Alzheimers Dis 2017; 57: 171– 81. 28222527
  19. [25]Bednarska-Makaruk M, Graban A, Sobczynska-Malefora A, Harrington DJ, Mitchell M, Voong K, Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia. Exp Gerontol 2016; 81: 83– 91. 27167582
  20. [26]Ferri E, Arosio B, D’Addario C, Galimberti D, Gussago C, Pucci M, Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer’s disease. J Neurol Sci 2016; 362: 283– 6. 26944164
  21. [27]Grossi E, Stoccoro A, Tannorella P, Migliore L, Coppede F. Artificial neural networks link one-carbon metabolism to gene-promoter methylation in Alzheimer’s disease. J Alzheimers Dis 2016; 53: 1517– 22. 27392858
  22. [28]Kobayashi N, Shinagawa S, Nagata T, Shimada K, Shibata N, Ohnuma T, Development of biomarkers based on DNA methylation in the NCAPH2/LMF2 promoter region for diagnosis of Alzheimer’s disease and amnesic mild cognitive impairment. PLoS One 2016; 11: e0146449. PMC4704831 26742120
  23. [29]Li H, Guo Z, Guo Y, Li M, Yan H, Cheng J, Common DNA methylation alterations of Alzheimer’s disease and aging in peripheral whole blood. Oncotarget 2016; 7: 19089– 98. 26943045 PMC4991367
  24. [30]Sung HY, Choi BO, Jeong JH, Kong KA, Hwang J, Ahn JH. Amyloid beta-mediated hypomethylation of heme oxygenase 1 correlateswith cognitive impairment in Alzheimer’s disease. PLoS One 2016; 11: e0153156. PMC4825942 27058954
  25. [31]Yamazaki K, Yoshino Y, Mori T, Okita M, Yoshida T, Mori Y, Association study and meta-analysis of polymorphisms, methylation profiles, and peripheral mRNA expression of the serotonin transporter gene in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2016; 41: 33– 47. 27414430
  26. [32]Yoshino Y, Mori T, Yoshida T, Yamazaki K, Ozaki Y, Sao T, Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer’s Disease Subjects. J Alzheimers Dis 2016; 54: 1349– 57. 27567856
  27. [33]Yu L, Chibnik LB, Yang J, McCabe C, Xu J, Schneider JA, Methylation profiles in peripheral blood CD41 lymphocytes versus brain: The relation to Alzheimer’s disease pathology. Alzheimers Dement 2016; 12: 942– 51. 27016692 PMC5014706
  28. [34]Carboni L, Lattanzio F, Candeletti S, Porcellini E, Raschi E, Licastro F, Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer’s disease patients. Neurosci Lett 2015; 605: 44– 8. 26275347
  29. [35]Di Francesco A, Arosio B, Falconi A, Micioni Di Bonaventura MV, Karimi M, Mari D, Global changes in DNA methylation in Alzheimer’s disease peripheral blood mononuclear cells. Brain Behav Immun 2015; 45: 139– 44. 25452147
  30. [36]Nagata T, Kobayashi N, Ishii J, Shinagawa S, Nakayama R, Shibata N, Association between DNA methylation of the BDNF promoter region and clinical presentation in Alzheimer’s disease. Dement Geriatr Cogn Disord Extra 2015; 5: 64– 73. PMC4376924 25873928
  31. [37]Tannorella P, Stoccoro A, Tognoni G, Petrozzi L, Salluzzo MG, Ragalmuto A, Methylation analysis of multiple genes in blood DNA of Alzheimer’s disease and healthy individuals. Neurosci Lett 2015; 600: 143– 7. 26079324
  32. [38]Chang L, Wang Y, Ji H, Dai D, Xu X, Jiang D, Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer’s disease. PLoS One 2014; 9: e110773. PMC4217733 25364831
  33. [39]Hernandez HG, Mahecha MF, Mejia A, Arboleda H, Forero DA. Global long interspersed nuclear element 1 DNA methylation in a Colombian sample of patients with late-onset Alzheimer’s disease. Am J Alzheimers Dis other Demen 2014; 29: 50– 3. 24164934 PMC11008131
  34. [40]Kaut O, Ramirez A, Pieper H, Schmitt I, Jessen F, Wullner U. DNA methylation of the TNF-alpha promoter region in peripheral blood monocytes and the cortex of human Alzheimer’sdiseasepatients. Dement Geriatr Cogn Disord 2014; 38: 10– 5. 24556805
  35. [42]Silva PN, Furuya TK, Braga IL, Rasmussen LT, Labio RW, Bertolucci PH, Analysis ofHSPA8 and HSPA9 mRNA expression and promoter methylation in the brain and blood of Alzheimer’s disease patients. J Alzheimers Dis 2014; 38: 165– 70. 23948933
  36. [43]Wang Y, Xu S, Cao Y, Xie Z, Lai C, Ji X, Folate deficiency exacerbates apoptosis by inducing hypomethylation and resultant overexpression of DR4 together with altering DNMTs in Alzheimer’s disease. Int J Clin Exp Med 2014; 7: 1945– 57. 25232375 PMC4161535
  37. [44]Di Francesco A, Arosio B, Gussago C, Dainese E, Mari D, D’Addario C, Involvement of 5-lipoxygenase in Alzheimer’s disease: A role for DNA methylation. J Alzheimers Dis 2013; 37: 3– 8. 23727898
  38. [45]Guan JZ, Guan WP, Maeda T, Makino N. Analysis of telomere length and subtelomeric methylation of circulating leukocytes in women with Alzheimer’s disease. Aging Clin Exp Res 2013; 25: 17– 23. 23740629
  39. [46]Hou Y, Chen H, He Q, Jiang W, Luo T, Duan J, Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer’s disease patients. Acta Neuropsychiatr 2013; 25: 66– 76. 25287307
  40. [47]Yu CE, Cudaback E, Foraker J, Thomson Z, Leong L, Lutz F, Epigenetic signature and enhancer activity of the human APOE gene. Hum Mol Genet 2013; 22: 5036– 47. 23892237 PMC3836480
  41. [48]Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, Pin1 contribution to Alzheimer’s disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer’s disease. Neurodegener Dis 2012; 10: 207– 11. 22261503
  42. [49]D’Addario C, Di Francesco A, Arosio B, Gussago C, Dell’Osso B, Bari M, Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 2012; 7: e39186. PMC3373611 22720070
  43. [50]Furuya TK, da Silva PN, Payao SL, Rasmussen LT, de Labio RW, Bertolucci PH, SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer’s Disease. Neurochem Int 2012; 61: 973– 5. 22836009
  44. [51]Furuya TK, Silva PN, Payao SL, Bertolucci PH, Rasmussen LT, De Labio RW, Analysis of SNAP25 mRNA expression and promoter DNA methylation in brain areas of Alzheimer’s disease patients. Neuroscience 2012; 220: 41– 6. 22732502
  45. [52]Guan JZ, Guan WP, Maeda T, Makino N. Effect of vitamin E administration on the elevated oxygen stress and the telomeric and subtelomeric status in Alzheimer’s disease. Gerontology 2012; 58: 62– 9. 21912072
  46. [53]Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, DNA methylation in repetitive elements and Alzheimer disease. Brain Behav Immun 2011; 25: 1078– 83. 21296655 PMC3742099
  47. [54]Liu HC, Hu CJ, Tang YC, Chang JG. A pilot study for circadian gene disturbance in dementia patients. Neurosci Lett 2008; 435: 229– 33. 18358604
  48. [55]Silva PN, Gigek CO, Leal MF, Bertolucci PH, De Labio RW, Payao SL, Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer’s disease. J Alzheimers Dis 2008; 13: 173– 6. 18376059
  49. [56]Speranca MA, Batista LM, Lourenco Rda S, Tavares WM, Bertolucci PH, Rigolin Vde O, Can the rDNA methylation pattern be used as a marker for Alzheimer’s disease? Alzheimers Dement 2008; 4: 438– 42. 19012869
  50. [57]Degerman S, Josefsson M, Nordin Adolfsson A, Wennstedt S, Landfors M, Haider Z, Maintained memory in aging is associated with young epigenetic age. Neurobiol Aging 2017; 55: 167– 71. 28292535
  51. [58]Funahashi Y, Yoshino Y, Yamazaki K, Mori Y, Mori T, Ozaki Y, DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. Psychiatry Clin Neurosci 2017; 71: 28– 35. 27685250
  52. [59]Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, An Epigenetic Signature in Peripheral Blood Associated with the Haplo-type on 17q21.31, a Risk Factor for Neurodegenerative Tauopathy. PLoS Genet 2014; 10: e1004211. PMC3945475 24603599
  53. [60]Galimberti D, D’Addario C, Dell’Osso B, Fenoglio C, Marcone A, Cerami C, Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol Sci 2013; 34: 899– 903. 22797721
  54. [62]Russ J, Liu EY, Wu K, Neal D, Suh ER, Irwin DJ, Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol 2015; 129: 39– 52. 25388784 PMC4282973
  55. [63]Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, Fratta P, The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol 2015; 129: 715– 27. 25716178
  56. [65]Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, Maletta RG, Hypermethylation of the CpG-island near the C9orf72 G4C2 repeat expansion in FTLD patients. Hum Mol Genet 2014; 23: 5630– 7. 24908669
  57. [66]Sun Z, Wu Y, Ordog T, Baheti S, Nie J, Duan X, Aberrant signature methylome by DNMT1 hot spot mutation in hereditary sensory and autonomic neuropathy 1E. Epigenetics 2014; 9: 1184– 93. 25033457 PMC4164503
  58. [67]Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 2011; 43: 595– 600. 21532572 PMC3102765
  59. [68]Sun L, Chen K, Li X, Xiao S. Rapidly progressive frontotemporal dementia associated with MAPT mutation G389R. J Alzheimers Dis 2017; 55: 777– 85. 27802239
  60. [69]Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546– 54. 9855500
  61. [70]Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456– 77. 21810890 PMC3170532
  62. [71]Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985– 92. 11735772
  63. [72]McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53: 902– 5. 10496243
  64. [73]McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113– 24. 8909416
  65. [74]McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 2001; 58: 1803– 9. 11708987
  66. [75]Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006– 14. 21325651 PMC3059138
  67. [76]Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293– 9. 11464847
  68. [77]Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994; 57: 416– 8. 8163988 PMC1072868
  69. [78]Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57: 1497– 9. 11673599
  70. [79]The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2016 Edition. Australia: The Joanna Briggs Institute; 2016.
  71. [80]de Rooij SR, Caan MW, Swaab DF, Nederveen AJ, Majoie CB, Schwab M, Prenatal famine exposure has sex-specific effects on brain size. Brain 2016; 139: 2136– 42. 27401522
  72. [82]Foraker J, Millard SP, Leong L, Thomson Z, Chen S, Keene CD, The APOE Gene is Differentially methylated in Alzheimer’s disease. J Alzheimers Dis 2015; 48: 745– 55. 26402071 PMC6469491
  73. [83]Chang SC, Koenen KC, Galea S, Aiello AE, Soliven R, Wildman DE, Molecular variation at the SLC6A3 locus predicts lifetime risk of PTSD in the Detroit Neighborhood Health Study. PLoS One 2012; 7: e39184. PMC3383758 22745713
  74. [85]Delgado-Morales R, Esteller M. Opening up the DNA methylome of dementia. Mol Psychiatry 2017; 22: 485– 96. 28044062 PMC5378809
  75. [88]Shad KF, Aghazadeh Y, Ahmad S, Kress B. Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse (New York, NY) 2013; 67: 541– 3. 23404438
  76. [89]Francois M, Leifert W, Martins R, Thomas P, Fenech M. Biomarkers of Alzheimer’s disease risk in peripheral tissues; focus on buccal cells. Curr Alzheimer Res 2014; 11: 519– 31. 24938500 PMC4166904
  77. [90]Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6– 21. 11782440
  78. [91]Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Cancer Res 2016; 76: 3446– 50. 27256564
  79. [92]Paul Y, Mondal B, Patil V, Somasundaram K. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Clin Epigenetics 2017; 9: 32. 28392842 PMC5379538
  80. [93]Stelzer Y, Shivalila CS, Soldner F, Markoulaki S, Jaenisch R. Tracing dynamic changes of DNA methylation at single-cell resolution. Cell 2015; 163: 218– 29. 26406378 PMC4583717
  81. [94]Denham J, Marques FZ, Bruns EL, O’Brien BJ, Charchar FJ. Epigenetic changes in leukocytes after 8 weeks of resistance exercise training. Eur J Appl Physiol 2016; 116: 1245– 53. 27155847
  82. [95]Jung KH, Lovinsky-Desir S, Yan B, Torrone D, Lawrence J, Jezioro JR, Effect of personal exposure to black carbon on changes in allergic asthma gene methylation measured 5 days later in urban children: importance of allergic sensitization. Clin Epigenetics 2017; 9: 61. 28588744 PMC5457544
  83. [96]Sant KE, Nahar MS, Dolinoy DC. DNA methylation screening and analysis. Methods Mol Biol (Clifton, NJ) 2012; 889: 385– 406. PMC3592359 22669678
  84. [97]Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. Biology (Basel) 2016; 5: 3. PMC4810160 26751487
  85. [98]Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011; 12: 529– 41. 21747404 PMC3508712
  86. [100]Zhao J, Zhu Y, Yang J, Li L, Wu H, De Jager PL, A genomewide profiling of brain DNA hydroxymethylation in Alzheimer’s disease. Alzheimers Dement 2017; 13: 674– 88. 28089213 PMC6675576
  87. [101]Shi C, Zhang L, Qin C. Long non-coding RNAs in brain development, synaptic biology, and Alzheimer’s disease. Brain Res Bull 2017; 132: 160– 9. 28347717
  88. [102]Sharma S, Taliyan R. Transcriptional dysregulation in Huntington’s disease: The role of histone deacetylases. Pharmacol Res 2015; 100: 157– 69. 26254871
  89. [103]Bernstein AI, Lin Y, Street RC, Lin L, Dai Q, Yu L, 5-Hydroxyme-thylation-associated epigenetic modifiers of Alzheimer’s disease modulate Tau-induced neurotoxicity. Hum Mol Genet 2016; 25: 2437– 50. 27060332 PMC5181627
  90. [105]Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 2017; 8: 111– 26. 28603768 PMC5454085
  91. [107]Gupta VB, Hone E, Pedrini S, Doecke J, O’Bryant S, James I, Altered levels of blood proteins in Alzheimer’s disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimers Dement (Amst) 2017; 8: 60– 72. 28508031 PMC5423327
  92. [108]Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics 2016; 8: 389– 99. 26673039 PMC4864062

Cited by

Sorted by citations

Authors
Fransquet, P. D., Lacaze, P., Saffery, R., McNeil, J., Woods, R., & Ryan, J.
Affiliations
  • The University of Melbourne (AU)
  • Monash University (AU)
  • Inserm (FR)
Corresponding author
Ryan, Joanne
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2017-11-08
Volume
14
Issue
1
Pages
81-103
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2017.10.002
PMC
PMC6810631
OpenAlex
W2767280000
Cited by
96
References
13
Citations by year
2026: 3 · 2025: 10 · 2024: 5 · 2023: 12 · 2022: 15 · 2021: 13 · 2020: 19 · 2019: 10 · 2018: 8 · 2016: 1
FWCI
1.87
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, other-oa)
  • Own your potential (DEAKIN) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Australian Government
  • Monash University
  • National Institute on Aging (U01AG029824)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
dementia, DNA methylation
MeSH terms
Dementia, Humans, Biomarkers, DNA Methylation, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review